Terminated EARLY_PHASE1 INTERVENTIONAL 1-arm NCT01337492

Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)

Pilot Study: Safety and Feasibility of Using Sorafenib as Neoadjuvant Treatment Prior to Orthotopic Liver Transplantation (OLT) in Patients With Hepatocellular Carcinoma

Sponsor: Bayer

Conditions Carcinoma, Hepatocellular

Interventions Nexavar

Updated 6 times since 2017 Last updated: Mar 20, 2012 Started: Sep 30, 2010 Primary completion: May 31, 2011 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

slow accrual

Other terminated trials from Bayer

See all terminations from Bayer

Other Carcinoma, Hepatocellular trials with similar outcome

Browse all Carcinoma, Hepatocellular trials

Listed as NCT01337492, this EARLY_PHASE1 trial focuses on Carcinoma, Hepatocellular and remains terminated or withdrawn. Sponsored by Bayer, it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated Phase 0

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Case Comprehensive Cancer Center
Onyx Therapeutics, Inc.

Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States